Promising Alzheimer's drug lecanemab tested in 1,900 patients

NCT ID NCT03887455

Disease control Sponsor: Eisai Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether lecanemab can slow memory and thinking decline in people with early Alzheimer's disease. About 1,900 participants received either the drug or a placebo for 18 months, followed by an open-label extension where everyone can get lecanemab. The main goal is to see if lecanemab preserves daily function and thinking skills better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,906 people

The number who actually took part.

Started

Mar 2019

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Core Study: Inclusion Criteria Diagnosis: Mild Cognitive Impairment (MCI) due to Alzheimer's disease - intermediate likelihood: * Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria for MCI due to Alzheimer's disease - intermediate likelihood * Have a global Clinical Dementia Rating (CDR) score of 0.5 and CDR Memory Box score of 0.5 or greater at Screening and Baseline * Report a history of subjective memory decline with gradual onset and slow progression over the last 1 year before Screening; must be corroborated by an informant Mild Alzheimer's disease dementia: * Meet the NIA-AA core clinical criteria for probable Alzheimer's disease dementia * Have a global CDR score of 0.5 to 1.0 and a CDR Memory Box score of 0.5 or greater at Screening and Baseline Key Inclusion Criteria that must be met by all participants: * Objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale IV-Logical Memory (subscale) II (WMS-IV LMII) * Positive biomarker for brain amyloid pathology * Male or female participants aged greater than or equal to (\>=) 50 and less than or equal to (\<=) 90 years, at the time of informed consent * Mini mental state examination (MMSE) score \>=22 at Screening and Baseline and \<=30 at Screening and Baseline * Body mass index (BMI) greater than (\>)17 and less than (\<) 35 at Screening * If receiving an approved Alzheimer's disease treatment such as acetylcholinesterase inhibitor (AChEIs) or memantine or both for Alzheimer's disease, must be on a stable dose for at least 12 weeks prior to Baseline. Treatment-naive participants for Alzheimer's disease can be entered into the study. Unless otherwise stated, participants must have been on stable doses of all other (that is, non-Alzheimer's disease-related) permitted concomitant medications for at least 4 weeks prior to Baseline. Use of memantine will not be allowed for participants in Japan * Have an identified study partner (defined as a person able to support the participant for the duration of the study and who spends at least 8 hours per week with the participant) * Provide written informed consent. If a participant lacks capacity to consent in the investigator's opinion, the participant's assent should be obtained, if required in accordance with local laws, regulations and customs, plus the written informed consent of a legal representative should be obtained (capacity to consent and definition of legal representative should be determined in accordance with applicable local laws and regulations). In countries where local laws, regulations, and customs do not permit participants who lack capacity to consent to participate in this study (example, Germany and Spain), they will not be enrolled Extension Phase: Inclusion Criteria: * Participants who have completed the Core Study (except de novo participants) * Must continue to have a study partner who is willing and able to provide follow-up information on the participant throughout the course of the Extension Phase * Provide written informed consent for the Extension Phase. If a participant lacks capacity to consent in the investigator's opinion, the participant's assent should be obtained, if required and in accordance with local laws, regulations and customs, plus the written informed consent of a legal representative should be obtained (capacity to consent and definition of legal representative should be determined in accordance with applicable local laws and regulations). In countries where local laws, regulations, and customs do not permit participants who lack capacity to consent to participate in this study (example, Germany and Spain), they will not be enrolled * Participants entering the SC (vial) substudy at Extension Phase Week 1, must be willing to participate, or continue participating in the amyloid positron emission tomography (PET) substudy. All participants must have an amyloid PET scan within 4 weeks before starting SC BAN2401 * Participants enrolling into the SC autoinjector substudy must have had at least 6 months exposure to BAN2401 10 mg/kg IV biweekly or at least 12 months exposure of BAN2401 Dose 1 subcutaneously weekly. * Participants enrolling into the SC Dose 3 autoinjector substudy must have previously received BAN2401 by either IV administration and/or SC autoinjector administration and must have completed Visit 82 (Extension Week 79) at a minimum, regardless of previous route of administration Extension Phase Part B: Inclusion Criteria: • Must have completed Week 207 in the Extension Phase Exclusion Criteria * Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's Alzheimer's disease * History of transient ischemic attacks (TIA), stroke, or seizures within 12 months of Screening * Any psychiatric diagnosis or symptoms (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant * Geriatric Depression Scale (GDS) score \>=8 at Screening * Contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (example in skull and cardiac devices other than those approved as safe for use in MRI scanners) * Evidence of other clinically significant lesions on brain MRI at Screening that could indicate a dementia diagnosis other than Alzheimer's disease * Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter \[mm\] or less at the greatest diameter); a single macrohemorrhage \>10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and \<1 centimeter \[cm\] at their greatest diameter need not be exclusionary) * Any immunological disease which is not adequately controlled, or which requires treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressants, or plasmapheresis during the study * Participants with a bleeding disorder that is not under adequate control (including a platelet count \<50,000 or international normalized ratio \[INR\] \>1.5 for participants who are not on anticoagulant treatment, example, warfarin). Participants who are on anticoagulant therapy should have their anticoagulant status optimized and be on a stable dose for 4 weeks before Screening. Participants who are on anticoagulant therapy are not permitted to participate in cerebrospinal fluid (CSF) assessments * Any other medical conditions (example, cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments * Participation in a clinical study involving any therapeutic monoclonal antibody, protein derived from a monoclonal antibody, immunoglobulin therapy, or vaccine within 6 months before screening unless it can be documented that the participant was randomized to placebo * Participation in a clinical study involving any anti-amyloid therapies (including any monoclonal antibody therapies and any β-site amyloid precursor protein cleaving enzyme \[BACE\] inhibitor therapies) unless it can be documented that the participant only received placebo * Participants who have any known prior exposure to lecanemab * Participants who were dosed in a clinical study involving any new chemical entities for AD within 6 months prior to screening unless it can be documented that the participant was in a placebo treatment arm Extension Phase: Exclusion Criteria * Participants who discontinued early from the Core Study * Participants who develop the following conditions from the time of Screening for the Core Study to the start of the Extension Phase * Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD * Any psychiatric diagnosis or symptoms, (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant * Contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (example, in skull and cardiac devices other than those approved as safe for use in MRI scanners) * Other significant pathological findings on brain MRI during the Core Study including but not limited to: cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors will be exclusionary if based on the opinion of the investigator, with consultation of medical monitor, these findings may interfere with the study procedures or safety * Hypersensitivity to BAN2401 or any of the excipients, or to any monoclonal antibody treatment * Any immunological disease which is not adequately controlled, or which requires chronic treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressants, or plasmapheresis during the study * Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or ECG, which in the opinion of the investigator require further investigation or treatment or which may interfere with study procedures or safety * Malignant neoplasms (except for basal or squamous cell carcinoma in situ of the skin, or localized prostate cancer in male participants) that are not stably and adequately controlled or which, based on the opinion of the investigator, may interfere with the participant's safety or participation in the study * Any other medical conditions (example, cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments * Severe visual or hearing impairment that would prevent the participant from performing psychometric tests accurately Extension Phase Part B: Exclusion Criteria -In countries where lecanemab is authorized for use in APOE4 noncarriers and heterozygous carriers only, APOE4 homozygous carriers will not be eligible for participation in Extension Phase Part B. Any APOE4 homozygous carriers that are already participating in Extension Phase Part B in such countries will be discontinued from the study.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early Alzheimer's disease

Contacts and locations

Locations

ANI Neurology, PLLC d/b/a Alzheimer's Memory Center

Charlotte, North Carolina, 28270, United States
ASST-Monza, Ospedale San Gerardo

Monza, 20900, Italy
ActivMed Practices & Research

Methuen, Massachusetts, 01844, United States
Advanced Clinical Research Network

Coral Gables, Florida, 33134, United States
Advanced Memory Research Institute of NJ, PC

Toms River, New Jersey, 08755, United States
Advanced Research Consultants, Inc.

Palm Beach Gardens, Florida, 33410, United States
Advocate Lutheran General Hospital

Park Ridge, Illinois, 60068, United States
Albany Medical College

Albany, New York, 12208, United States
Alliance for Multispecialty Research LLC, New Orleans Center for Clinical Research / Volunteer Research Group, an AMR company

Knoxville, Tennessee, 37920, United States
Allied Biomedical Research (Clinical Trial)

Miami, Florida, 33155, United States
Alzheimer's Research and Treatment Center

Lake Worth, Florida, 33449, United States
Alzheimer's Research and Treatment Center

Stuart, Florida, 34997, United States
Apex Research Institute

Santa Ana, California, 92705, United States
Asan Medical Center

Seoul, 05505, South Korea
Associated Neurologists of Southern Connecticut

Fairfield, Connecticut, 06824, United States
Austin Health - Medical and Cognitive Research Unit

Ivanhoe, Victoria, 3081, Australia
Australian Alzheimer's Research Foundation

Nedlands, Western Australia, 6009, Australia
Azienda Ospedaliero Universitaria Pisana

Pisa, 56126, Italy
Banner Alzheimer's Institute- Clinical Trials Department

Phoenix, Arizona, 85006, United States
Banner Sun Health Research

Sun City, Arizona, 85351, United States
Baotou Central Hospital

Baotou, Inner Mongolia, 014040, China
Baylor College of Medicine AD and Memory Disorders Center

Houston, Texas, 77030, United States
Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, 100050, China
Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, 100070, China
Bio Behavioral Health

Toms River, New Jersey, 08755, United States
BioMed Research Institute

Miami, Florida, 33126, United States
Bioclinica Research

Orlando, Florida, 32806, United States
Bioclinica Research

The Villages, Florida, 32162, United States
Boston Center for Memory

Newton, Massachusetts, 02459, United States
Bradenton Research Center, Inc.

Bradenton, Florida, 34205, United States
Brain Matters Research

Delray Beach, Florida, 33445, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Butler Hospital - Memory and Aging Program

Providence, Rhode Island, 02906, United States
CCM Clinical Research Group

Miami, Florida, 33133, United States
Central Adelaide Local Health Network, The Queen Elizabeth Hospital and the Royal Adelaide Hospital

Woodville South, Adelaid, South Australia, 5011, Australia
Centre de Recherche Clinique du Gérontopôle

Toulouse, Haute Garonne, 31059, France
Centro CAE Oroitu

Getxo, Bizkaia, 48993, Spain
Charing Cross Hospital

London, W6 8RF, United Kingdom
Charter Research

Lady Lake, Florida, 32159, United States
Chonnam National University Hospital

Gwangju, Jeolla-do, 61469, South Korea
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Cleveland Clinic Lou Ruvo Center for Brain Health

Las Vegas, Nevada, 89106, United States
Clincloud, LLC

Maitland, Florida, 32751, United States
Clinica Neurologica, IRCCS Ospedale Policlinico San Martino, Genova

Genova, 16132, Italy
Clinical Trial Network

Houston, Texas, 77074, United States
Coastal Neurology, P.A.

Port Royal, South Carolina, 29935, United States
Columbs Neuroscience, LLC

Columbus, Ohio, 43020, United States
Columbus Memory Center

Columbus, Georgia, 31909, United States
Complejo Hospitalario Ruber Juan Bravo

Madrid, 28006, Spain
DBA The Memory Clinic

Bennington, Vermont, 05201, United States
Donald S. Marks, MD. P.C.

Plymouth, Massachusetts, 02360, United States
Dong-A University Hospital

Busan, 49201, South Korea
Eisai Trial Site #1

Bielefeld, 33647, Germany
Eisai Trial Site #1

Fujioka-shi, Gunma, 3750017, Japan
Eisai Trial Site #10

Shinjuku-ku, Tokyo, 160-8582, Japan
Eisai Trial Site #11

Osaka, 5458586, Japan
Eisai Trial Site #12

Musashino-shi, Tokyo, 180-8610, Japan
Eisai Trial Site #13

Hachioji-shi, Tokyo, 193-0998, Japan
Eisai Trial Site #14

Ube-shi, Yamaguchi, 755-8505, Japan
Eisai Trial Site #15

Chiba, Chiba, 260-8656, Japan
Eisai Trial Site #16

Kurashiki-shi, Okayama-ken, 7100813, Japan
Eisai Trial Site #17

Fujisawa-shi, Kanagawa, 2510038, Japan
Eisai Trial Site #18

Saitama-shi, Saitama, 338-8577, Japan
Eisai Trial Site #19

Kobe, Hyōgo, 6500017, Japan
Eisai Trial Site #2

Mannheim, Baden-Wurttemberg, D-68159, Germany
Eisai Trial Site #2

Yokohama, Kanagawa, 2350012, Japan
Eisai Trial Site #20

Kawasaki-shi, Kanagawa, 2118533, Japan
Eisai Trial Site #21

Hōfu, Yamaguchi, 7470802, Japan
Eisai Trial Site #22

Niigata, Niigata, 9500983, Japan
Eisai Trial Site #23

Shinagawa-ku, Tokyo, 142-0054, Japan
Eisai Trial Site #24

Toride-shi, Ibaraki, 302-0004, Japan
Eisai Trial Site #25

Shinjuku-ku, Tokyo, 160-0023, Japan
Eisai Trial Site #26

Suita-shi, Osaka, 565-0871, Japan
Eisai Trial Site #27

Osaka, 5560017, Japan
Eisai Trial Site #28

Himeji-shi, Hyōgo, 6700981, Japan
Eisai Trial Site #29

Bunkyo-ku, Tokyo, 180-8610, Japan
Eisai Trial Site #3

München, 81675, Germany
Eisai Trial Site #3

Yamagata, Yamagata, 9900834, Japan
Eisai Trial Site #30

Sapporo, Hokkaido, 650033, Japan
Eisai Trial Site #31

Ōtsu, Shiga, 520-2192, Japan
Eisai Trial Site #32

Ōtake, Hiroshima, 7390696, Japan
Eisai Trial Site #33

Higashimorokatagun, Miyazaki, 880-1111, Japan
Eisai Trial Site #4

Erbach im Odenwald, 64711, Germany
Eisai Trial Site #4

Obu-shi, Aichi-ken, 4748511, Japan
Eisai Trial Site #5

Günzburg, Baden-Wurttemberg, 89312, Germany
Eisai Trial Site #5

Bunkyo-ku, Tokyo, 113-0034, Japan
Eisai Trial Site #6

Berlin, 12203, Germany
Eisai Trial Site #6

Yoshida-gun, Fukui, 9101193, Japan
Eisai Trial Site #7

Atsugi-shi, Kanagawa, 2438551, Japan
Eisai Trial Site #8

Hirakata, Osaka, 5731121, Japan
Eisai Trial Site #9

Kahoku, Ishikawa-ken, 920-0293, Japan
Emory University Cognitive Neurology Clinic & ADRC

Atlanta, Georgia, 30329, United States
Finlay Medical Research

Miami, Florida, 33126, United States
First Moscow State Medical University n.a. I.M. Sechenov

Moscow, 119991, Russia
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico - U.O.S.D. Malattie Neurodegenerative

Milan, 20122, Italy
Fondazione Istituto G.Giglio di Cefalù

Cefalù, Palermo, 90015, Italy
Fondazione Policlinico Agostino Gemelli - UCSC

Roma, 00168, Italy
Fort Wayne Neurological Center

Fort Wayne, Indiana, 46804, United States
Fundacion ACE, Barcelona

Barcelona, 08028, Spain
Fundación CITA-alzheimer Findazioa

Donostia / San Sebastian, Gipuzkoa, 20009, Spain
Galiz Research

Miami Springs, Florida, 33016, United States
Georgetown University Hospital

Washington D.C., District of Columbia, 20057, United States
Gonzalez MD & Aswad MD Health Services

Miami, Florida, 33125, United States
Great Lakes Clinical Trials

Chicago, Illinois, 60640, United States
Groupe Hospitalier Pitie-Salpetriere

Paris, Cedex, 75013, France
Guangdong Provincial People's Hospital

Guangzhou, Guangzhou, 510080, China
Guangzhou First People's Hospital

Guangzhou, Guangdong, 510180, China
Guangzhou Huiai Hospital

Guangzhou, Guangdong, 510450, China
HammondCare Malvern Clinical Trials Unit

Malvern, Victoria, 3144, Australia
Hanyang University Seoul Hospital

Seoul, 04763, South Korea
Hattiesburg Clinic

Hattiesburg, Mississippi, 39401, United States
Hawaii Pacific Neuroscience

Honolulu, Hawaii, 96817, United States
Health Research

West Vancouver, British Columbia, V7T 1C5, Canada
Henan Provincial People's Hospital

Zhengzhou, Henan, 450003, China
Hopital Guillaume et RenÃ LaÃnnec

Nantes, Cedex, 44093, France
Hopital de la Timone

Marseille, Cedex 05, 13385, France
Hospital Clinic i Provincial de Barcelona

Barcelona, 08036, Spain
Hospital General de Catalunya

Sant Cugat del Vallès, Barcelona, 08195, Spain
Hospital Santa Cruz y San Pablo

Barcelona, 8025, Spain
Hospital Universitari i Politècnic La Fe

Valencia, 46026, Spain
Hospital Universitario Reina Sofía

Córdoba, 14011, Spain
Hospital Victoria Eugenia - Cruz Roja

Seville, 41009, Spain
Hospital de Salamanca

Salamanca, 37005, Spain
Hôpital Gui de Chauliac

Montpellier, Cedex 5, 34295, France
Hôpital Lariboisière

Paris, Paris, 75010, France
Hôpital de Hautepierre

Strasbourg, Bas Rhin, 67200, France
Hôpital neurologique Pierre Wertheimer

Bron, 69500, France
IMIC, Inc.

Palmetto Bay, Florida, 33157, United States
ImmunoE Research Center

Centennial, Colorado, 80112, United States
Indiana University School of Medicine

Indianapolis, Indiana, 46202, United States
Infinity Clinical Research

Hollywood, Florida, 33024, United States
Infinity Clinical Research, LLC

Sunrise, Florida, 33351, United States
Inha University Hospital

Incheon, 22332, South Korea
Institute for Neurodegenerative Disorders

New Haven, Connecticut, 06510, United States
Irvine Clinical Research

Irvine, California, 92614, United States
JEM Research Institute

Atlantis, Florida, 33462, United States
Jinan Central Hospital

Jinan, Shandong, 250013, China
KU Wichita Center for Clinical Research

Wichita, Kansas, 67214, United States
KaRa Institute of Neurological Diseases

Macquarie Park, New South Wales, 2229, Australia
Karolinska University Hospital

Stockholm, 141 86, Sweden
Kawartha Centre - Redefining Healthy Aging

Peterborough, Ontario, K9H 2P4, Canada
Kerwin Research Center

Dallas, Texas, 75231, United States
Keystone Clinical Studies, LLC

Norristown, Pennsylvania, 19403, United States
Kingfisher Cooperative LLC

Spokane, Washington, 99202, United States
Konkuk University Medical Center

Seoul, 05030, South Korea
Las Vegas Medical Research

Las Vegas, Nevada, 89113, United States
Linfritz Research Institute, Inc.

Coral Gables, Florida, 33134, United States
Lynn Health Science Institute

Oklahoma City, Oklahoma, 73112, United States
Memory Assessment & Research Centre (MARC),

Southampton, Hampshire, SO30 3JB, United Kingdom
Memory Clinic, Malmö University Hospital

Malmö, 20502, Sweden
Miami Jewish Health Systems

Miami, Florida, 33137, United States
Mile High Research Center

Denver, Colorado, 80218, United States
MoCA Clinic and Institute/NeuroSearch Developpements Inc.

Greenfield Park, Quebec, J4V 2J2, Canada
Nanjing Brain Hospital, Affiliated to Nanjing Medical University

Nanjing, Jiangsu, 210029, China
Nanjing Drum Tower Hospital

Nanjing, Jiangsu, 210008, China
National Clinical Research Inc.-Richmond

Richmond, Virginia, 23294, United States
National University Hospital

Singapore, 119228, Singapore
Neural Net Research, LLC

Portland, Oregon, 97225, United States
NeuroStudies.net, LLC

Decatur, Georgia, 30033, United States
Neurological Associates of Albany, PC

Albany, New York, 12208, United States
Neurological Associates of Tucson dba Center for Neurosciences

Tucson, Arizona, 85718, United States
Neurological Institute of New York

New York, New York, 10032, United States
Neurology Associates of Ormond Beach

Ormond Beach, Florida, 32174, United States
Neurology Center of North Orange County

Fullerton, California, 92835, United States
Neurology Clinic, P.C.

Cordova, Tennessee, 38018, United States
Neuropsychiatric Research Center of Southwest FL

Fort Myers, Florida, 33912, United States
Neurostudies, Inc.

Port Charlotte, Florida, 33952, United States
New York University Medical Center PRIME

New York, New York, 10016, United States
North Bay Neuroscience Research Institute

Sebastopol, California, 95472, United States
OH Clinical Research Partners

Canton, Ohio, 44718, United States
Ohio State University

Columbus, Ohio, 43221, United States
Okanagan Clinical Trials

Kelowna, British Columbia, V1Y 1Z9, Canada
Oregon Health & Science University

Portland, Oregon, 97239, United States
Ospedale "Card. G. Panico" -

Tricase, LE, 73039, Italy
Ospedale S. Maria della Misericordia, S. Andrea delle Fratte

Perugia, 06132, Italy
PMG Research of Winston Salem

Winston-Salem, North Carolina, 27103, United States
Pacific Neuroscience Medical Group

Oxnard, California, 93030, United States
Pacific Research Network, Inc

San Diego, California, 92103, United States
Partners Population Health

Belmont, Massachusetts, 02478, United States
Pharmax Research of South Florida, Inc

Miami, Florida, 33175, United States
Policlinica Guipuzcoa

Donostia / San Sebastian, Guipuzcoa, 20014, Spain
Premiere Research Institute, West Palm

West Palm Beach, Florida, 33407, United States
Prima Clinica Neurologica, Primo Policlinico AOU "L. Vanvitelli"

Naples, 80138, Italy
Progressive Medical Research

Port Orange, Florida, 32127, United States
Q&T Research Sherbrooke Inc.

Sherbrooke, Quebec, J1J 2G2, Canada
Qinghai Provincial People's Hospital

Xining, Qinghai, 810007, China
Quantum Laboratories Inc.

Pompano Beach, Florida, 33064, United States
Raleigh Neurology Associates, P.A. - Research Department

Raleigh, North Carolina, 27607, United States
Re:Cognition Health

Plymouth, Devon, PL6 8BT, United Kingdom
Re:Cognition Health Ltd

Birmingham, B16 8LT, United Kingdom
Re:Cognition Health Ltd

Guildford, GU2 7YD, United Kingdom
Re:Cognition Health Ltd

London, W1G 9JF, United Kingdom
Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Mémoire de l'Outaouais

Gatineau, Quebec, J8T 8JI, Canada
Recherches Neuro-Hippocampe, Inc., d/b/a Ottawa Memory Clinic

Ottawa, Ontario, K1Z 1G3, Canada
Renji Hospital Shanghai Jiaotong Universtiy School of Medicine

Shanghai, Shanghai Municipality, 200215, China
Renstar Medical Research

Ocala, Florida, 34470, United States
Research Center for Clinical Studies, Inc.

Norwalk, Connecticut, 06851, United States
Rhode Island Hospital

Providence, Rhode Island, 02903, United States
Rhode Island Mood & Memory Research Institute

East Providence, Rhode Island, 02914, United States
Rios Medical Center, Inc.

Miami, Florida, 33135, United States
Roper St. Francis Healthcare

North Charleston, South Carolina, 29406, United States
Sahlgrenska University Hospital

Gothenburg, Västra Götalandslän, 43141, Sweden
Samsung Medical Center

Seoul, 06351, South Korea
Senior Adult Specialty Research

Austin, Texas, 78757, United States
Seoul National University Boramae Medical Center

Seoul, 07061, South Korea
Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 13620, South Korea
Seoul National University Bundang Hospital

Seongnam-si, Seoul, 13620, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Severance Hospital, Yonsei University Health System

Seoul, 03722, South Korea
Shanghai Sixth People's Hospital

Shanghai, Shanghai Municipality, 200233, China
Shanghai Tongji Hospital

Shanghai, Shanghai Municipality, 200065, China
Sharp Mesa Vista Hospital

San Diego, California, 92123, United States
Sheffield Memory Service

Sheffield, South Yorkshire, S5 7JT, United Kingdom
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310016, China
St Joseph Heritage Healthcare

Santa Rosa, California, 95403, United States
St Vincent's Hospital - Translational Research Centre

Darlinghurst, New South Wales, 2010, Australia
St. Joseph's HC- Parkwood Institute

London, Ontario, N6C 0A7, Canada
St. Pancras Clinical Research

London, EC2Y 8 EA, United Kingdom
Stanford University Medical Center

Palo Alto, California, 94304, United States
Stedman Clinical Trials, LLC

Tampa, Florida, 33613, United States
Summit Research Network (OR) Inc.

Portland, Oregon, 97210, United States
Sun Yat-Sent Memorial Hospital of Sun Yat-Sen University

Guangzhou, Guangdong, 510120, China
Texas Neurology, PA

Dallas, Texas, 75214, United States
The Catholic University of Korea, Seoul ST. Mary's Hospital

Seoul, 06591, South Korea
The First Bethune Hospital of Jilin University

Changchun, Jilin, 130000, China
The Prince Charles Hospital/Internal Medicine & Dementia Research Unit

Chermside Brisbane, Queensland, 4032, Australia
The Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, 50000, China
Tianjin Huanhu Hospital

Tianjin, Tianjin Municipality, 300350, China
Toronto Memory Program (Neurology Research Inc.)

Toronto, Ontario, M3B 2S7, Canada
True North Clinical Research Halifax, Inc.

Halifax, Nova Scotia, B3S 1M7, Canada
True North Clinical Research Kentville, Inc.

Kentville, Nova Scotia, B4N 4K9, Canada
UCSF Memory and Aging Center

San Francisco, California, 94158, United States
USF Suncoast Gerontology Center

Tampa, Florida, 33613, United States
Universita' Sapienza di Roma - Dipartimento di Neuroscienze Umane

Roma, 00185, Italy
University of California - Los Angeles

Los Angeles, California, 90045, United States
University of Kansas Medical Center Research Institute

Kansas City, Kansas, 66160, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Rochester

Rochester, New York, 14620, United States
Uppsala University Hospital, Uppsala

Uppsala, 751 85, Sweden
Visionary Investigators Network

Miami, Florida, 33137, United States
Visionary Investigators Network

Miami, Florida, 33180, United States
Vitae Research Center

Miami, Florida, 33135, United States
Washington University

St Louis, Missouri, 63108, United States
Xiangya Hospital Central South University

Changsha, Hunan, 410008, China
Xuanwu Hospital Capital Medical University

Beijing, Beijing Municipality, 100053, China
Yale University School Of Medicine

New Haven, Connecticut, 06510, United States
iResearch Atlanta, LLC

Decatur, Georgia, 30030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.